WO1999003503A1 - The use of angiostatic steroids in photodynamic therapy - Google Patents
The use of angiostatic steroids in photodynamic therapy Download PDFInfo
- Publication number
- WO1999003503A1 WO1999003503A1 PCT/US1998/012711 US9812711W WO9903503A1 WO 1999003503 A1 WO1999003503 A1 WO 1999003503A1 US 9812711 W US9812711 W US 9812711W WO 9903503 A1 WO9903503 A1 WO 9903503A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- neovascularization
- angiostatic
- steroids
- diol
- pregnadien
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0027—Azides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69825906T DE69825906T2 (en) | 1997-07-16 | 1998-06-18 | USE OF ANGIOSTATIC STEROIDS IN PHOTODYNAMIC THERAPY |
AT98931367T ATE274356T1 (en) | 1997-07-16 | 1998-06-18 | USE OF ANGIOSTATIC STEROIDS IN PHOTODYNAMIC THERAPY |
US09/445,237 US6297228B1 (en) | 1991-11-22 | 1998-06-18 | Use of angiostatic steroids in photodynamic therapy |
AU81515/98A AU734195B2 (en) | 1997-07-16 | 1998-06-18 | The use of angiostatic steroids in photodynamic therapy |
JP2000502798A JP2001510170A (en) | 1997-07-16 | 1998-06-18 | Methods and uses of anti-angiogenic steroids in photodynamic therapy |
CA002296558A CA2296558A1 (en) | 1997-07-16 | 1998-06-18 | The use of angiostatic steroids in photodynamic therapy of ocular neovascularization |
BR9811012-8A BR9811012A (en) | 1997-07-16 | 1998-06-18 | "use of a compound". |
EP98931367A EP1003553B1 (en) | 1997-07-16 | 1998-06-18 | The use of angiostatic steroids in photodynamic therapy |
HK00107465A HK1028952A1 (en) | 1997-07-16 | 2000-11-22 | The use of angiostatic steroids in photodynamic therapy. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/895,184 | 1997-07-16 | ||
US08/895,184 US5770592A (en) | 1991-11-22 | 1997-07-16 | Prevention and treatment of ocular neovascularization using angiostatic steroids |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/456,432 Continuation US6372723B1 (en) | 1997-06-18 | 1999-12-08 | Compositions and methods for preventing restenosis following revascularization procedures |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999003503A1 true WO1999003503A1 (en) | 1999-01-28 |
Family
ID=25404127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/012711 WO1999003503A1 (en) | 1991-11-22 | 1998-06-18 | The use of angiostatic steroids in photodynamic therapy |
Country Status (13)
Country | Link |
---|---|
US (2) | US5770592A (en) |
EP (1) | EP1003553B1 (en) |
JP (1) | JP2001510170A (en) |
AT (1) | ATE274356T1 (en) |
AU (1) | AU734195B2 (en) |
BR (1) | BR9811012A (en) |
CA (1) | CA2296558A1 (en) |
DE (1) | DE69825906T2 (en) |
DK (1) | DK1003553T3 (en) |
ES (1) | ES2224412T3 (en) |
HK (1) | HK1028952A1 (en) |
PT (1) | PT1003553E (en) |
WO (1) | WO1999003503A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001058240A2 (en) * | 2000-02-10 | 2001-08-16 | Massachusetts Eye And Ear Infirmary | Photodynamic therapy for treating conditions of the eye |
US6602274B1 (en) | 1999-01-15 | 2003-08-05 | Light Sciences Corporation | Targeted transcutaneous cancer therapy |
EP1539182A1 (en) * | 2002-08-05 | 2005-06-15 | Alcon, Inc. | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
EP1570859A2 (en) * | 2000-03-24 | 2005-09-07 | Novartis AG | Improved treatment of neovascularization |
WO2005102297A2 (en) * | 2004-04-23 | 2005-11-03 | Alcon, Inc. | Angiostatic agents for controlling choroidal neovascularisation after ocular surgery of trauma |
EP2278978A2 (en) * | 2008-05-28 | 2011-02-02 | Validus Biopharma, Inc. | Non-hormonal steroid modulators of nf-kb for treatment of disease |
US8158669B2 (en) | 2000-03-24 | 2012-04-17 | Qlt, Inc. | Method for treating neovascularization |
US9198921B2 (en) | 2010-04-05 | 2015-12-01 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-κB for treatment of disease |
US10799514B2 (en) | 2015-06-29 | 2020-10-13 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-kappa beta for treatment of disease |
US11382922B2 (en) | 2019-03-07 | 2022-07-12 | Reveragen Biopharma, Inc. | Aqueous oral pharmaceutical suspension compositions |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2358296A1 (en) * | 1999-01-05 | 2000-07-13 | Anthony P. Adamis | Targeted transscleral controlled release drug delivery to the retina and choroid |
AU2412800A (en) | 1999-01-15 | 2000-08-01 | Light Sciences Corporation | Noninvasive vascular therapy |
JP2002534483A (en) * | 1999-01-15 | 2002-10-15 | ライト サイエンシーズ コーポレイション | Therapeutic compositions for metabolic bone disorders or bone metastases |
CA2383572C (en) | 1999-10-21 | 2007-12-11 | Alcon Universal Ltd. | Sub-tenon drug delivery |
ATE283013T1 (en) | 1999-10-21 | 2004-12-15 | Alcon Inc | MEDICATION DELIVERY DEVICE |
US6416777B1 (en) | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
US7943162B2 (en) * | 1999-10-21 | 2011-05-17 | Alcon, Inc. | Drug delivery device |
US7678836B2 (en) * | 1999-11-04 | 2010-03-16 | Fxs Ventures, Llc | Method for rendering a contact lens wettable |
US8679089B2 (en) | 2001-05-21 | 2014-03-25 | Michael S. Berlin | Glaucoma surgery methods and systems |
AU2001263324A1 (en) * | 2000-05-19 | 2001-12-03 | Michael S. Berlin | Laser delivery system and method of use for the eye |
US9603741B2 (en) | 2000-05-19 | 2017-03-28 | Michael S. Berlin | Delivery system and method of use for the eye |
JP2004536631A (en) | 2001-05-03 | 2004-12-09 | マサチューセッツ・アイ・アンド・イア・インファーマリー | Implantable drug delivery device and use thereof |
AU2002319606B2 (en) * | 2001-07-23 | 2006-09-14 | Alcon, Inc. | Ophthalmic drug delivery device |
EP1409065B1 (en) | 2001-07-23 | 2007-01-17 | Alcon, Inc. | Ophthalmic drug delivery device |
EP1434786A4 (en) * | 2001-10-03 | 2009-03-25 | Merck & Co Inc | Androstane 17-beta-carboxamides as androgen receptor modulators |
PL371929A1 (en) * | 2001-11-09 | 2005-07-11 | Eyetech Pharmaceuticals | Methods for treating ocular neovascular diseases |
US6723750B2 (en) | 2002-03-15 | 2004-04-20 | Allergan, Inc. | Photodynamic therapy for pre-melanomas |
AU2003217531A1 (en) * | 2002-05-02 | 2003-11-17 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
AU2003254650B2 (en) | 2002-07-24 | 2010-09-09 | Qlt, Inc. | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents |
US6806364B2 (en) * | 2002-07-29 | 2004-10-19 | Ast Products, Inc. | Ophthalmic compositions |
AU2003259301A1 (en) * | 2002-07-29 | 2004-02-16 | Ast Products, Inc. | Ophtalmic compositions |
US6828356B2 (en) * | 2002-07-29 | 2004-12-07 | Ast Products, Inc. | Preparation of ophthalmic compositions |
DE10238310A1 (en) * | 2002-08-21 | 2004-03-04 | Erich Jaeger Gmbh | electrode assembly |
JP2006501902A (en) * | 2002-10-03 | 2006-01-19 | ライト サイエンシズ コーポレイション | System and method for exciting photosensitive compounds in ocular tissue |
WO2004073551A2 (en) * | 2003-02-18 | 2004-09-02 | Massachusetts Eye And Ear Infirmary | Transscleral drug delivery device and related methods |
JP2006518383A (en) * | 2003-02-20 | 2006-08-10 | アルコン,インコーポレイテッド | Glucocorticoid formulations for treating pathological ocular angiogenesis |
PL378210A1 (en) * | 2003-02-20 | 2006-03-20 | Alcon, Inc. | Use of steroids to treat ocular disorders |
JP2007500250A (en) * | 2003-06-13 | 2007-01-11 | アルコン,インコーポレイテッド | Nonsteroidal anti-inflammatory drug formulations for treating pathological ocular angiogenesis |
EP1635842A4 (en) * | 2003-06-20 | 2007-04-04 | Alcon Inc | Treatment of amd with combination of ingredients |
ZA200508654B (en) * | 2003-07-10 | 2007-01-31 | Alcon Inc | Ophthalmic drug delivery device |
AU2004274026A1 (en) * | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
WO2005032510A1 (en) * | 2003-09-23 | 2005-04-14 | Alcon, Inc. | Triamcinolone acetonide and anecortave acetate formulations for injection |
WO2005072744A1 (en) * | 2004-02-02 | 2005-08-11 | Yuichi Kaji | Vitreous-visualizing agents |
CN1980929A (en) * | 2004-02-24 | 2007-06-13 | 比奥阿克松医疗技术股份有限公司 | 4-substituted piperidine derivatives |
US20160106717A1 (en) | 2004-09-24 | 2016-04-21 | Gen Pharma Holdings LLC | Cai-based systems and methods for the localized treatment of uveitis |
CA2581126A1 (en) | 2004-09-24 | 2006-04-06 | Rfe Pharma Llc | Carboxy-amido-triazoles for the localized treatment of ocular diseases |
US20060107555A1 (en) * | 2004-11-09 | 2006-05-25 | Curtis Marc D | Universal snow plow adapter |
US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
KR101387456B1 (en) | 2005-02-09 | 2014-04-21 | 산텐 세이야꾸 가부시키가이샤 | Liquid formulations for treatment of diseases or conditions |
US9839719B2 (en) | 2005-05-25 | 2017-12-12 | Cis Pharma Ag | Biocompatible polymers and co-polymers, and uses thereof |
PL1919290T3 (en) * | 2005-07-12 | 2014-06-30 | Ampio Pharmaceuticals Inc | Methods and products for treatment of diseases |
CN101600475A (en) | 2005-07-27 | 2009-12-09 | 佛罗里达大学研究基金会有限公司 | Revise the miniaturization compound and the use thereof of protein false folding |
US7261529B2 (en) * | 2005-09-07 | 2007-08-28 | Southwest Research Institute | Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents |
UA94060C2 (en) | 2005-09-07 | 2011-04-11 | Эмджен Фримонт Инк. | Monoclonal antibodies that specifically binds alk-1 |
US7758778B2 (en) * | 2005-09-07 | 2010-07-20 | Southwest Research Institute | Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents |
US9693967B2 (en) * | 2005-09-07 | 2017-07-04 | Southwest Research Institute | Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates |
WO2007047626A1 (en) * | 2005-10-14 | 2007-04-26 | Alcon, Inc. | Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis |
WO2007047744A2 (en) * | 2005-10-14 | 2007-04-26 | Alcon, Inc. | Method for treating primary and secondary forms of glaucoma |
US20080125406A1 (en) * | 2005-10-14 | 2008-05-29 | Robin Alan L | Method for Treating Primary and Secondary Forms of Glaucoma |
JP2009514969A (en) | 2005-11-09 | 2009-04-09 | コンビナトアールエックス インコーポレーティッド | Methods, compositions, and kits for treating medical conditions |
MX2008006379A (en) | 2005-11-29 | 2009-03-03 | Smithkline Beecham Corp | Treatment method. |
EP2001438A2 (en) | 2006-02-09 | 2008-12-17 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
DK2001466T3 (en) | 2006-03-23 | 2016-02-29 | Santen Pharmaceutical Co Ltd | LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES |
US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
US20170360609A9 (en) | 2007-09-24 | 2017-12-21 | Ivantis, Inc. | Methods and devices for increasing aqueous humor outflow |
US20090181933A1 (en) * | 2008-01-11 | 2009-07-16 | Bingaman David P | Use of steroids to treat persons suffering from ocular disorders |
AU2009221859B2 (en) | 2008-03-05 | 2013-04-18 | Alcon Inc. | Methods and apparatus for treating glaucoma |
US8372036B2 (en) | 2009-05-06 | 2013-02-12 | Alcon Research, Ltd. | Multi-layer heat assembly for a drug delivery device |
IN2012DN00352A (en) | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
CA2765883A1 (en) * | 2009-06-22 | 2010-12-29 | Dmi Acquisition Corp. | Methods and products for treatment of diseases |
DE202010017530U1 (en) | 2009-06-22 | 2012-03-28 | Dmi Acquisition Corp. | Danazol compound for the treatment of diseases |
CN102481404B (en) | 2009-07-09 | 2014-03-05 | 伊万提斯公司 | Ocular implants |
EP2451375B1 (en) | 2009-07-09 | 2018-10-03 | Ivantis, Inc. | Single operator device for delivering an ocular implant |
US20120232102A1 (en) | 2009-09-30 | 2012-09-13 | Chun-Fang Xu | Methods Of Administration And Treatment |
US8177747B2 (en) | 2009-12-22 | 2012-05-15 | Alcon Research, Ltd. | Method and apparatus for drug delivery |
US20120283557A1 (en) | 2011-05-05 | 2012-11-08 | Berlin Michael S | Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses |
US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
EA032666B1 (en) | 2011-06-14 | 2019-06-28 | Бикам Фармасьютикалз, Инк. | Opsin-binding ligands and methods of use thereof |
EP2768307B1 (en) | 2011-10-19 | 2020-03-18 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
US9353063B2 (en) | 2011-11-30 | 2016-05-31 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
CA2862746A1 (en) | 2011-12-01 | 2013-06-06 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
US8663150B2 (en) | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
US10617558B2 (en) | 2012-11-28 | 2020-04-14 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
KR20150105355A (en) | 2012-12-19 | 2015-09-16 | 앰피오 파마슈티컬스 인코퍼레이티드 | Method for treatment of diseases |
US10709547B2 (en) | 2014-07-14 | 2020-07-14 | Ivantis, Inc. | Ocular implant delivery system and method |
US10149856B2 (en) | 2015-01-26 | 2018-12-11 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
US10857157B2 (en) | 2015-01-26 | 2020-12-08 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
US10106525B2 (en) | 2015-01-26 | 2018-10-23 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
JP6837475B2 (en) | 2015-08-14 | 2021-03-03 | イバンティス インコーポレイテッド | Ocular implant and delivery system with pressure sensor |
WO2017106517A1 (en) | 2015-12-15 | 2017-06-22 | Ivantis, Inc. | Ocular implant and delivery system |
US11198680B2 (en) | 2016-12-21 | 2021-12-14 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
WO2019014322A1 (en) | 2017-07-11 | 2019-01-17 | BioAxone BioSciences, Inc. | Kinase inhibitors for treatment of disease |
AU2022205382A1 (en) | 2021-01-11 | 2023-06-22 | Alcon Inc. | Systems and methods for viscoelastic delivery |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991019731A1 (en) * | 1990-06-11 | 1991-12-26 | The Upjohn Company | Steroids which inhibit angiogenesis |
US5371078A (en) * | 1988-10-31 | 1994-12-06 | Alcon Laboratories, Inc. | Angiostatic steroids and methods and compositions for controlling ocular hypertension |
WO1995024930A1 (en) * | 1994-03-14 | 1995-09-21 | Massachusetts Eye & Ear Infirmary | Use of green porphyrins in ocular diagnosis and therapy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4975537A (en) * | 1985-10-23 | 1990-12-04 | The Upjohn Company | Δ9(11) -angiostatic steroids |
US4771042A (en) * | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
US4876250A (en) * | 1988-10-31 | 1989-10-24 | Alcon Laboratories, Inc. | Methods for controlling ocular hypertension with angiostatic steroids |
-
1997
- 1997-07-16 US US08/895,184 patent/US5770592A/en not_active Expired - Fee Related
-
1998
- 1998-06-18 JP JP2000502798A patent/JP2001510170A/en active Pending
- 1998-06-18 DE DE69825906T patent/DE69825906T2/en not_active Expired - Fee Related
- 1998-06-18 ES ES98931367T patent/ES2224412T3/en not_active Expired - Lifetime
- 1998-06-18 EP EP98931367A patent/EP1003553B1/en not_active Expired - Lifetime
- 1998-06-18 DK DK98931367T patent/DK1003553T3/en active
- 1998-06-18 PT PT98931367T patent/PT1003553E/en unknown
- 1998-06-18 US US09/445,237 patent/US6297228B1/en not_active Expired - Fee Related
- 1998-06-18 AT AT98931367T patent/ATE274356T1/en not_active IP Right Cessation
- 1998-06-18 CA CA002296558A patent/CA2296558A1/en not_active Abandoned
- 1998-06-18 AU AU81515/98A patent/AU734195B2/en not_active Ceased
- 1998-06-18 WO PCT/US1998/012711 patent/WO1999003503A1/en active IP Right Grant
- 1998-06-18 BR BR9811012-8A patent/BR9811012A/en not_active Application Discontinuation
-
2000
- 2000-11-22 HK HK00107465A patent/HK1028952A1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5371078A (en) * | 1988-10-31 | 1994-12-06 | Alcon Laboratories, Inc. | Angiostatic steroids and methods and compositions for controlling ocular hypertension |
WO1991019731A1 (en) * | 1990-06-11 | 1991-12-26 | The Upjohn Company | Steroids which inhibit angiogenesis |
WO1995024930A1 (en) * | 1994-03-14 | 1995-09-21 | Massachusetts Eye & Ear Infirmary | Use of green porphyrins in ocular diagnosis and therapy |
Non-Patent Citations (6)
Title |
---|
ABBOT F. CLARK: "AL-3789: a novel ophtalmic angiostatic steroid", EXPERT. OPIN. INVEST. DRUGS., vol. 6, no. 12, December 1997 (1997-12-01), pages 1867 - 1877, XP002082568 * |
ANDERSON C. ET AL.: "Phtalocyanine Photodynamic Therapy: Disparate effects of Pharmacologic Inhibitors on Cutaneous Photosensitivity and on Tumor Regression", PHOTOCHEMISTRY AND PHOTOBIOLOGY, vol. 65, no. 5, May 1997 (1997-05-01), pages 895 - 901, XP002082567 * |
COWLED P.A. ET AL.: "Potentiation of Photodynamic Therapy with Haematoporphyrin Derivatives by Glucocorticoids", CANCER LETTERS, vol. 29, 1985, pages 107 - 114, XP002081606 * |
DATABASE DISSERTATION ABSTRACTS University Microfilms International; 1996, DEFALLER JOSEPH MICHAEL: "Mechanism of action and clinical efficay of AL-3789, an angiostatic steroid", XP002082569 * |
MILLER J W ET AL: "PHOTODYNAMIC THERAPY OF EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION USING LIPOPROTEIN-DELIVERED BENZOPORPHYRIN", ARCHIVES OF OPHTHALMOLOGY, vol. 113, no. 6, June 1995 (1995-06-01), pages 810 - 818, XP000672344 * |
VERINDER S. NIRANKARI: "Laser Photocoagulation for Corneal Stromal Vascularization", TRANS. AM. OPHTALMOL. SOC., vol. 90, 1992, pages 565 - 669, XP002082566 * |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6602274B1 (en) | 1999-01-15 | 2003-08-05 | Light Sciences Corporation | Targeted transcutaneous cancer therapy |
US7125542B2 (en) | 2000-02-10 | 2006-10-24 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
WO2001058240A3 (en) * | 2000-02-10 | 2002-04-11 | Massachusetts Eye & Ear Infirm | Photodynamic therapy for treating conditions of the eye |
JP2003530146A (en) * | 2000-02-10 | 2003-10-14 | マサチューセッツ・アイ・アンド・イア・インファーマリー | Photodynamic therapy to treat eye conditions |
JP2013082746A (en) * | 2000-02-10 | 2013-05-09 | Massachusetts Eye & Ear Infirmary | Photodynamic therapy for treating condition of eye |
JP2010065057A (en) * | 2000-02-10 | 2010-03-25 | Massachusetts Eye & Ear Infirmary | Photodynamic therapy for treating condition of eye |
WO2001058240A2 (en) * | 2000-02-10 | 2001-08-16 | Massachusetts Eye And Ear Infirmary | Photodynamic therapy for treating conditions of the eye |
EP1570859A3 (en) * | 2000-03-24 | 2008-04-02 | Novartis AG | Improved treatment of neovascularization |
EP1570859A2 (en) * | 2000-03-24 | 2005-09-07 | Novartis AG | Improved treatment of neovascularization |
US8862224B2 (en) | 2000-03-24 | 2014-10-14 | Valeant Pharmceuticals International, Inc. | Method for treating neovascularization |
US8158669B2 (en) | 2000-03-24 | 2012-04-17 | Qlt, Inc. | Method for treating neovascularization |
EP1539182A4 (en) * | 2002-08-05 | 2010-01-20 | Alcon Inc | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
EP1539182A1 (en) * | 2002-08-05 | 2005-06-15 | Alcon, Inc. | Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
WO2005102297A3 (en) * | 2004-04-23 | 2006-01-05 | Alcon Inc | Angiostatic agents for controlling choroidal neovascularisation after ocular surgery of trauma |
WO2005102297A2 (en) * | 2004-04-23 | 2005-11-03 | Alcon, Inc. | Angiostatic agents for controlling choroidal neovascularisation after ocular surgery of trauma |
EP2444092A1 (en) * | 2008-05-28 | 2012-04-25 | Validus Biopharma, Inc. | Non-hormonal steroid modulators of nf-kb for treatment of disease |
US9649320B2 (en) | 2008-05-28 | 2017-05-16 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-κB for treatment of disease |
US8334279B2 (en) | 2008-05-28 | 2012-12-18 | Validus Genetics | Non-hormonal steroid modulators of NF-κB for treatment of disease |
EP2278978A4 (en) * | 2008-05-28 | 2011-06-15 | Validus Biopharma Inc | Non-hormonal steroid modulators of nf-kb for treatment of disease |
CN102076344B (en) * | 2008-05-28 | 2013-11-13 | 瓦利杜斯生物医药有限公司 | Non-hormonal steroid modulators of nf-kb for treatment of disease |
US8673887B2 (en) | 2008-05-28 | 2014-03-18 | Reveragen Biopharma, Inc | Non-hormonal steroid modulators of NF-kB for treatment of disease |
CN103739647A (en) * | 2008-05-28 | 2014-04-23 | 雷沃根生物医药有限公司 | Non-hormonal steroid modulators of nf-kb for treatment of disease |
EP2278978A2 (en) * | 2008-05-28 | 2011-02-02 | Validus Biopharma, Inc. | Non-hormonal steroid modulators of nf-kb for treatment of disease |
AU2009260471B2 (en) * | 2008-05-28 | 2014-12-11 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-KB for treatment of disease |
US11833159B2 (en) | 2008-05-28 | 2023-12-05 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-kB for treatment of disease |
US9434758B2 (en) | 2008-05-28 | 2016-09-06 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-κB for treatment of disease |
US8207151B2 (en) | 2008-05-28 | 2012-06-26 | Validus Biopharma Inc. | Non-hormonal steroid modulators of NF-κB for treatment of disease |
CN103739647B (en) * | 2008-05-28 | 2017-06-09 | 雷沃根生物医药有限公司 | Non- steroid conditioning agent for treating the NF κ B of disease |
US10857161B2 (en) | 2008-05-28 | 2020-12-08 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-kB for treatment of disease |
US10206933B2 (en) | 2008-05-28 | 2019-02-19 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-kB for treatment of disease |
US10000525B2 (en) | 2010-04-05 | 2018-06-19 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-κB for treatment of disease |
US9198921B2 (en) | 2010-04-05 | 2015-12-01 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-κB for treatment of disease |
US10799514B2 (en) | 2015-06-29 | 2020-10-13 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-kappa beta for treatment of disease |
US11690853B2 (en) | 2015-06-29 | 2023-07-04 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-κβ for treatment of disease |
US11382922B2 (en) | 2019-03-07 | 2022-07-12 | Reveragen Biopharma, Inc. | Aqueous oral pharmaceutical suspension compositions |
US11471471B2 (en) | 2019-03-07 | 2022-10-18 | Reveragen Biopharma, Inc. | Aqueous oral pharmaceutical suspension compositions |
Also Published As
Publication number | Publication date |
---|---|
EP1003553A1 (en) | 2000-05-31 |
US5770592A (en) | 1998-06-23 |
ATE274356T1 (en) | 2004-09-15 |
EP1003553B1 (en) | 2004-08-25 |
CA2296558A1 (en) | 1999-01-28 |
HK1028952A1 (en) | 2001-03-16 |
ES2224412T3 (en) | 2005-03-01 |
DE69825906D1 (en) | 2004-09-30 |
BR9811012A (en) | 2000-10-17 |
AU8151598A (en) | 1999-02-10 |
US6297228B1 (en) | 2001-10-02 |
AU734195B2 (en) | 2001-06-07 |
DE69825906T2 (en) | 2005-09-01 |
DK1003553T3 (en) | 2004-09-20 |
PT1003553E (en) | 2004-10-29 |
JP2001510170A (en) | 2001-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1003553B1 (en) | The use of angiostatic steroids in photodynamic therapy | |
US5679666A (en) | Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids | |
EP0614463B1 (en) | Angiostatic steroids | |
US6011023A (en) | Angiostatic steroids | |
WO2005074942A1 (en) | Slow release steroid composition | |
JPH0725679B2 (en) | Intraocular pressure control agent | |
JP2007056041A (en) | Glucocorticoid prescription for treating neovascularization in morbid eye | |
US20060211662A1 (en) | Combination therapy for topical application in the treatment of age-related macular degeneration and ocular hypertension | |
US5929111A (en) | A-seco steroids effective at treating ophthalmic pathological neovascularization and controlling intraocular pressure | |
CA2064478C (en) | Ophthalmic composition | |
US5358943A (en) | Use of tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids | |
MXPA99011140A (en) | The use of angiostatic steroids in photodynamic therapy | |
US20080234245A1 (en) | Angiostatic Agents for Controlling Choroidal Neovascularisation After Ocular Surgery or Trauma | |
WO1997041867A1 (en) | Use of steroid compounds to prevent non-cancerous tissue growth | |
CN1239161C (en) | Method for treating dry eye disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA JP MX US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998931367 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/011140 Country of ref document: MX Ref document number: 09445237 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 81515/98 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2296558 Country of ref document: CA Kind code of ref document: A Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1998931367 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 81515/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998931367 Country of ref document: EP |